Comparative Pharmacology
Head-to-head clinical analysis: CYCLACILLIN versus KETEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLACILLIN versus KETEK.
CYCLACILLIN vs KETEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
250-500 mg orally every 6 hours.
Telithromycin 800 mg orally once daily for 7-10 days.
None Documented
None Documented
0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderatePrimarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Category C
Category C
Antibiotic
Antibiotic, Ketolide
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."